Exercise and Nutrition Programme Added to Weight-Loss Medication in Adults With Obesity
Tests whether exercise and nutrition support plus incretin medication helps adults with obesity keep muscle.
Plain-language title generated from the registry record
Registry title: Incretin-based Therapies, Nutrition, and Physical Activity
Key facts
- Where
- Québec, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07409831, who can take part
Where in Canada
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université LavalQuébec, CanadaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Laval University
- Trial code
- NCT07409831
- Record updated
- 16 July 2026
- Original description
The goal of this clinical trial is to evaluate whether combining a six-month structured lifestyle intervention (physical activity and nutrition) with incretin-based weight-loss medication improves preservation of muscle mass and physical function in adults living with obesity, compared with medication alone, and to assess the feasibility of a collaborative hospital-community care model.Read full original descriptionShow less
Holistic Approach to Cardiometabolic Health and Obesity: Incretin-based Therapies, Nutrition, and Active Lifestyle
The goal of this clinical trial is to evaluate whether combining a six-month structured lifestyle intervention (physical activity and nutrition) with incretin-based weight-loss medication improves preservation of muscle mass and physical function in adults living with obesity, compared with medication alone, and to assess the feasibility of a collaborative hospital-community care model.
This one-year pilot study will recruit 120 adults aged 18-70 years with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with at least one comorbidity) receiving routine obesity care at the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval. All participants will initiate physician-prescribed incretin-based therapy as part of standard care. The intervention group will receive medication plus a six-month structured lifestyle program delivered in collaboration with an exercise facility, including supervised strength-focused exercise and bi-monthly nutrition counseling, followed by a six-month consolidation phase. The control group will receive medication alone. Outcomes will be assessed at baseline and at 3, 6, and 12 months.
Participants will be randomly assigned in a 1:1 ratio to either the medication-only group or the combined medication and lifestyle intervention group. Participants randomized in the medication only group will receive a personalized consult with both a registered dietician and kinesiologist at the end of the study.
Inclusion: Adults aged 18 to 70 years; Prescribed, but not yet initiated, incretin-based pharmacotherapy [e.g., GLP-1 receptor agonist or dual GIP/GLP1 agonist] living with obesity, defined as:; BMI >30 kg/m2, or; BMI >27 kg/m2 with presence of comorbidities (e.g., type II diabetes, hypertension, hypercholesterolemia).
Exclusion: Prior or ongoing incretin-based therapy or history of bariatric surgery; Medical contraindications to physical activity practice (e.g., unstable cardiovascular disease, severe orthopedic limitation); Chronic conditions affecting protein metabolism or nutrition (e.g., advanced kidney disease, active cancer); Pregnancy, current breastfeeding or planned pregnancy during the study period; Implemented medical devices (e.g. pacemaker, defibrillator).